Shots:
- Biocon Biologics has signed a settlement and license agreement with Regeneron and Bayer for Yesafili (Biosimilar, Eylea) in the EU and globally, following a prior US and Canada settlement
- Biocon Biologics, Regeneron, and Bayer settled all pending litigation, allowing Yesafili’s UK launch in Jan’26 and other countries by Mar’26 or earlier. YESAFILI launched in Canada in 2024, and US market entry secured in April 2025, for H2’26 or earlier in certain circumstances
- Yesafili (40mg/ml) is a VEGF inhibitor for treating various eye conditions
Ref: Biocon Biologics | Image: Biocon Biologics, Regeneron, and Bayer| Press Release
Related News: Viatris Enters Agreement to Monetize Equity Stake in Biocon Biologics for ~$815M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
